Fig. 1

The effect of dasatinib on LPS-induced proinflammatory cytokine levels in BV2 microglial cells. a Structure of dasatinib. b BV2 microglial cells were treated with vehicle (1% DMSO) or dasatinib (100, 250, 500, 750, or 1000 nM) for 24 h, and MTT assays were conducted (n = 14 experimental replicates per dose). c BV2 microglial cells were treated with vehicle (1% DMSO) or dasatinib (100, 250, 500, 750, or 1000 nM) for 24 h, and BrdU proliferation assays were conducted (100 nM, n = 5; 250 nM, n = 5; 500 nM, n = 5; 750 nM, n = 5; or 1000 nM, n = 5). d BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (200 ng/ml) or PBS for 23 h 30 min, and MTT assays were performed (con, n = 6; LPS, n = 6; dasatinib+LPS, n = 6). e BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (200 ng/ml) or PBS for 23 h 30 min, and BrdU proliferation assays were performed (con, n = 6; LPS, n = 6; dasatinib+LPS, n = 6). f–k BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 μg/ml) or PBS for 5.5 h, and proinflammatory cytokine levels were measured by RT-PCR (COX2, IL-1β, and TNF-alpha: con, n = 21; LPS, n = 21; dasatinib+LPS, n = 21; IL-6 and iNOS: con, n = 44; LPS, n = 44; dasatinib+LPS, n = 44). l, m BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with anti-COX2 and anti-CD11b antibodies (con, n = 32; LPS, n = 54; dasatinib+LPS, n = 34). n BV2 microglial cells were treated with vehicle (1% DMSO) or dasatinib (250 nM) for 30 min followed by LPS (100 ng/ml) or PBS for 23 h 30 min. Levels of nitric oxide (NO) were measured using the Griess assay (con, n = 20; LPS, n = 20; dasatinib+LPS, n = 20). Two-tailed t tests (b, c) and one-way ANOVA with Tukey’s post hoc test (d–n) were used to analyze significant differences. **p < 0.01, ***p < 0.001